cancer assays

VolitionRx is preparing a reimbursement submission for its Nu.Q® cancer assays, a key step for wider market adoption. These blood-based diagnostic tools utilize proprietary technology for early cancer detection, aligning with precision medicine trends. Successful reimbursement is crucial for VolitionRx to accelerate market penetration, demonstrating the clinical and economic value of their innovative platform. This move could also pave the way for other liquid biopsy technologies in the growing early cancer detection market.